Dysfunction of polymorphonuclear leukocytes in uremia

Seminars in Nephrology

Volumn 16, Issue 3, 1996, Pages 192-201

  Haag Weber, Marianne ^a   Hörl, Walter H ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; BETA 2 MICROGLOBULIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT FACTOR D; CUPROPHANE; DEFEROXAMINE; FERRITIN; IMMUNOGLOBULIN LIGHT CHAIN; MICROBIAL ENZYME; PARA CRESOL; PARATHYROID HORMONE; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; UREMIC TOXIN;

BIOCOMPATIBILITY; CALCIUM CELL LEVEL; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS MEMBRANE; HEMODIALYSIS; HOST RESISTANCE; HUMAN; IRON OVERLOAD; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE DISORDER; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; UREMIA;

CALCIUM; HEMOSIDEROSIS; HUMANS; NEUTROPHILS; RENAL DIALYSIS; UREMIA;

EID: 0029874952     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Montgomerie JZ, Kalmanson GM, Guze LB: Renal failure and infection. Medicine (Baltimore) 47:1-32, 1968
2. Nsouli KA, Lazarus M, Schoenbaum SC, el al: Bacteremic infection in hemodialysis. Arch Intern Med 139:1255-1258, 1979
3. Lowrie EG, Lazarus JM, Mocelin AJ, el al: Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 288:863-867, 1973
4. Berman SJ, Hess JR, Sugihara JG, el al: Morbidity of infection in chronic hemodialysis. Dial Transplant 8:324-328, 1979
5. Bradley JR, Evans DB, Calne RY: Long-term survival in hemodialysis patients. Lancet 1:295-296, 1987
6. Quarles LD, Rutsky EA, Rostand SG: Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 6:412-419, 1985
7. Kaplowitz LG, Comstock JA, Landwehr DM, el al: A prospective study of infections in hemodialysis patients: Patient hygiene and other risk factors of infection. Infect Control Hosp Epidemiol 9:534-541, 1988
8. Keane WF, Shapiro FL, Raij L: Incidence and type of infections occuring in 445 chronic hemodialysis patients. ASAIO Trans 23:41-47, 1977
9. Mailloux LU, Bellucci AG, Wilkes BM, el al: Mortality in dialysis patients: Analysis of the causes of death. Am J Kidney Dis 18:326-335, 1991
10. Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 9:138-144, 1994 (Suppl 2)
11. Lundin AP, Adler AJ, Feinroth MV, el al: Maintenance hemodialysis. Survival beyond the first decade. JAMA 244:38-40, 1980
12. Degoulet P, Legrain M, Reach I, el al: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31:103-110, 1982
13. Neff MS, Eiser AR, Slifkin RF, el al: Patients surviving 10 years of hemodialysis. Am J Med 74:996-1004, 1983
14. Laurent G, Calemard E, Charra B: Long dialysis: A review of fifteen years experience in one centre 1968-1983. Proc Eur Dial Transplant Assoc 20:122-125, 1983
15. Keane WF, Maddy MM: Host defenses and infectious complications in maintenance hemodialysis patients, in Maher JF (ed): Replacement of Renal Function by Dialysis, 3rd ed. Kluwer Academic, 1989, pp 868-880
16. Hoen B, Kessler M, Hestin D, Mayeux D: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
17. Ifudu O, Brezsnyak WF, Reydel C, el al: Pathobiology and functional status of long-term hemodialysis patients. Am J Nephrol 15:379-385, 1995
18. Ward RA: Phagocytic cell function as an index of biocompatibility. Nephrol Dial Transplant 9:46-56, 1994 (Suppl 2)
19. Briggs WA, Sillix DH, Mahajan S, McDonald FD: Leukocyte metabolism and function in uremia. Kidney Int 16:S93-S96, 1983 (Suppl)
20. Haag-Weber M, Hable M, Fiedler G, el al: Alterations of polymorphonuclear leukocyte glycogen metabolism and glucose uptake in dialysis patients. Am J Kidney Dis 27:562-568, 1991
21. Haag-Weber M, Hörl WH: Uremia and infections: Mechanisms of impaired cellular host defense. Nephron 63:125-131, 1993
22. Haag-Weber M, Dumann M, Hörl WH: Effect of malnutrition and uremia on impaired cellular host defence. Miner Electrolyte Metab 18:174-185, 1992
23. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 3:1541-1554, 1993
24. Vanholder R, van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44:208-214, 1993
25. Boelaert JR, Cantinieaux BF, Hariga C, Fondu PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5:504-507, 1990
26. Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG: Impaired phagocytosis in dialysis patients: Studies on mechanisms. Am J Nephrol 11:102-111, 1991
27. 3 or calcium channel blocker. Am J Nephrol 13:467-472, 1993
28. i and carbohydrate metabolism of PMNL of dialysis patients. Kidney Int 47:1741-1745, 1995
29. Vanholder R, DeSmet R, Waterloos MA, el al: Mechanisms of uremic inhibition of phagocyte reactive species pro-duction: Characterization of the role of p-cresol. Kidney Int 47:510-517, 1995
30. Haag-Weber M, Hörl WH: The immune system in uremia and during its treatment. New Horizons 3:669-679, 1995
31. Tielemans C, Lenclud C, Collart F, el al: Iron status and infections in hemodialysis. Nephrol Dial Transplant 2:441, 1987 (abstr)
32. Tielemans C, Lenclud C: Respective role of hemosideresis and desferrioxamine therapy in the risk from infection of hemodialysed patients. Q J Med 68:573-574, 1988
33. Seifert A, von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65:1015-1024, 1987
34. Boelaert JR, van Landuyt HW, Valde YJ, el al: The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis 156:384-387, 1987
35. van Asbeck BS, Verbrugh HA, van Oost BA, el al: Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J Clin Res 284:542-544, 1982
36. Cantinieaux B, Boelaert J, Hariga C, Fondu P: Impaired neutrophil defense against Yersinia enterocolitica patients with iron overload who are undergoing dialysis. J Lab Clin Med 111:524-528, 1988
37. Cantineaux B, Hariga C, Ferster A, el al: Neutrophil dysfunction in thalassaemia major: The role of cell iron overload. Eur J Haematol 39:28-34, 1987
38. Waterlot Y, Cantineaux B, Hariga-Muller C, el al: Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J 291:501-504, 1985
39. Hoepelman IM, Jaarsma EY, Verhoef J, Marx JJ: Effect of iron on polymorphonuclear granulocyte phagocytic capacity: Role of oxidation state and effect of ascorbic acid. Br J Haematol 70:495-500, 1988
40. van Asbeck BS, Marx JJM, Struyvenberg A, el al: Effect of iron (III) in the presence of various ligands on the phagocytic and metabolic activity of human polymorphonuclear leukocytes. J Immunol 132:851-856, 1984
41. Flament J, Goldman M, Waterlot Y, el al: Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25:227-230, 1986
42. Massry SG, Fadda GZ: Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 21:81-86, 1993
43. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219-231, 1994
44. Shurtz-Swirski R, Shkolnik T, Shasha SM: Parathyroid hormone and the cellular immune system. Nephron 70:21-24, 1995
45. 2 consumption by PMNL from humans and rats with CRF: Role of secondary hyperparathyroidism. Kidney Int 42:602-609, 1992
46. Haag-Weber M, Hörl WH: Effect of biocompatible membranes on neutrophil function and metabolism. Clin Nephrol 42:S31-S36, 1994 (Suppl 1)
47. Haag-Weber M, Mai B, Hörl WH: Effect of hemodialysis on intracellular calcium in human polymorphonuclear neutrophils. Miner Electrolyte Metab 18:151-155, 1992
48. Craddock PR, Fehr J, Dalmasso AP, el al: Hemodialysis leukopenia: Pulmonary vascular leukostasis resulting from complement activation by dialyser cellophane membrane. J Clin Invest 59:879-888, 1977
49. Descamps-Latscha B, Herbelin A: Long-term dialysis and cellular immunity: A critical survey. Kidney Int 44:S135-S142, 1993 (Suppl)
50. Himmelfarb J, Zaoui P, Hakim R: Modulation of granulocyte LAM-1 and MAC-1 during dialysis - A prospective, randomized controlled trial. Kidney Int 41:388-395, 1992
51. Himmelfarb J, Ault KA, Holbrook D, el al: Intradialytic granulocyte reactive oxygen species production: A prospective, crossover trial. J Am Soc Nephrol 4:178-186, 1993
52. Kuwahara T, Markert M, Wauters JP: Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 3:661-665, 1988
53. Hirabayashi Y, Kobayashi T, Nishikawa A, el al: Oxidative metabolism and phagocytosis of polymorphonuclear leukocytes in patients with chronic renal failure. Nephron 49:305-312, 1988
54. Himmelfarb J, Lazarus M, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 17:271-276, 1991
55. Nguyen AT, Lethias C, Zingraff J, el al: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 28:158-167, 1985
56. Cristol JP, Canaud B, Rabesandratana H, el al: Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant 9:389-394, 1994
57. Rosenkranz AR, Tempi E, Traindl O, el al: Reactive oxygen product formation by human neutrophils as an early marker for biocompatibility of dialysis membranes. Clin Exp Immunol 98:300-305, 1994
58. Hörl WH, Steinhauer HB, Schollmeyer P: Plasma levels of granulocyte elastase during hemodialysis: Effects of different membranes. Kidney Int 28:791-796, 1985
59. Haag-Weber M, Schollmeyer P, Hörl WH: Granulocyte activation during haemodialysis in the absence of complement activation: Inhibition by calcium channel blockers. Eur J Clin Invest 18:380-385, 1988
60. Hörl WH, Steinhauer HB, Riegel W, el al: Effect of different dialyzer membranes on plasma levels of granulocyte elastase. Kidney Int 33:S90-S91, 1988
61. Shurtz-Swirski R, Mashiach E, Kristal B, el al: Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal railure. Nephron 71:176-179, 1995
62. Ward RA, McLeish KR: Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 5:1697-1702, 1995
63. Tielemans CL, Delville JPC, Husson CP, el al: Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 39:158-165, 1993
64. Thylén P, Fernvik E, Lundahl J, el al: Cell surface receptor modulation on monocytes and granulocytes during clinical and experimental hemodialysisAm J Nephrol 15:392-400, 1995
65. Lonnemann G, Bingel M, Floege J, el al: Detection of endotoxin-Iike interleukin-1-inducing activity during in vitro dialysis. Kidney Int 33:29-35, 1988
66. Laude-Sharp M, Caroff M, Simard L, el al: Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxins (LPS). Kidney Int 38:1089-1094, 1990
67. McLeish KR, Wellhausen SR, Dean WL: Biochemical basis of HLA-DR and CR3 modulation on human peripheral blood monocytes by lipopolysaccharide. Cellular Immunol 108:242-248, 1987
68. Arnaout MA, Hakim RM, Todd RF III, el al: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312:457-462, 1985
69. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990
70. Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037-1050, 1990
71. Arnaout MA: Leukocyte adhesion molecules deficiency: Its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol Rev 114:145-180, 1990
72. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates. Distinction from and prerequisite for adhesion through integrins. Cell 65:859-873, 1991
73. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 3:1227-1237, 1992
74. Craddock PR, Hammerschmidt DE: Complement mediated granulocyte activation and down-regulation during hemodialysis. ASAIO J 7:50-56, 1984
75. Lo SK, Detmers PA, Levin SM, Wright SD: Transient adhesion of neutrophils to endothelium. J Exp Med 169:1779-1793, 1989
76. Himmelfarb J, Gerard NP, Hakim RM: Intradialytic modulation of granulocyte C5a receptors. J Am Soc Nephrol 2:920-926, 1991
77. Hörl WH, Schaefer RM, Hörl M, Heidland A: Neutrophil activation in acute renal failure and sepsis. Arch Surg 125:651-654, 1990
78. Dofferhoff AS, De Jong HJ, Bom VJ, el al: Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scand J Infect Dis 24:197-204, 1992
79. Alvarez V, Pulido R, Campanero MR, el al: Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 40:899-905, 1991
80. 2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Kidney Int 43:649-660, 1993
81. Thylén P, Lundahl J, Fernvik E, el al: Mobilization of an intracellular glycoprotein (Mac-1) on monocytes and granulocytes during hemodialysis. Am J Nephrol 12:393-400, 1992
82. Kolb G, Fischer W, Schoenemann H, el al: Effect of cuprophan, hemophan and polysulfone membranes on the oxidative metabolism, degranulation reaction, enzyme release and pulmonary sequestration of granulocytes. Contrib Nephrol 74:10-21, 1989
83. Lundahl J, Hed J, Jacobson SH: Dialysis granulocytopenia is preceded by an increased surface expression of the adhesion-promoting glucoprotein Mac-1. Nephron 61:163-169, 1992
84. Haag-Weber M, Mai B, Hörl WH: Effect of hemodialysis on intracellular calcium in human polymorphonuclear neutrophils. Miner Electrolyte Metab 18:151-155, 1992
85. Haag-Weber M, Mai B, Deppisch R, el al: Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate. Clin Nephrol 41:245-251, 1994
86. Albertine KH, Cerasoli F, Tahamont MV, el al: Zymosan activated plasma causes prolonged decrease in PMN superoxide release in sheep. J Appl Physiol 67:2481-2490, 1989
87. McKenna PJ, Rosolia DL, Ishihara Y, el al: Downregulation of blood and bone marrow neutrophils decreases expression of acute lung injury in sheep. Am J Physiol 263.-H1492-H1498, 1992
88. Lewis SL, Van Epps DE, Chenoweth DE: C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients. Clin Nephrol 26:37-44, 1986
89. Cohen MS, Elliott DM, Chaplinski T, el al: A defect in the oxidative metabolism of human polymorphonuclear leukocytes that remain in circulation early in hemodialysis. Blood 60:1283-1289, 1982
90. Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int 39:320-327, 1991
91. Vanholder R, Ringoir S: Polymorphonuclear cell function and infection in dialysis. Kidney Int 42:S-91-S-95, 1992 (Suppl 38)
92. Himmelfarb J, Gerard NP, Hakim RM: Intradialytic modulation of granulocyte C5a receptors. J Am Soc Nephrol 2:920-926, 1991
93. Lewis SL, Van Epps DE: Neutrophil and monocyte alterations in chronic dialysis patients. Am J Kidney Dis 9:381-395, 1987
94. Moore FD, Davis C, Rodrick M, el al: Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 314:948-953, 1986
95. Nelson RD, McCormack RT, Fiegel VD, el al: Chemotactic deactivation of human neutrophils: Possible relationship to stimulation of oxidative metabolism. Infect Immunol 23:282-286, 1979
96. Solomkin JS, Cotta LA, Ogle JD, el al: Complement-induced expression of cryptic receptors on the neutrophil surface: A mechanism for regulation of acute inflammation in trauma. Surgery 96:336-344, 1984
97. Sunder-Plassmann G, Hörl WH: Can hemodialysis technique modify the hypercatabolic state? Renal Failure (in press)
98. Bone RC: Inhibitors of complement and neutrophils: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 20:891-898, 1992
99. Gardinali M, Padalino P, Vesconi S, el al: Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease. Arch Surg 127:1219-1224, 1992
100. Schulman G, Fogo A, Gung A, el al: Complement activation retards resolution of ischemic renal failure in the ratKidney Int 40:1069-1074, 1991
101. Schiffl H, Lang SM, König A, el al: Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 344:570-572, 1994
102. Hakim RM, Wingard RL, Parker RA: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 331:1338-1342, 1994
103. Woodrow G, Tumey JH: Cause of death in acute renal failure. Nephrol Dial Transplant 7:230-234, 1992
104. Masuda M, Kuriki M, Komiyama Y, el al: Measurement of membrane fluidity of polymorphonuclear leukocytes by flow cytometry. J Immunol Methods 96:225-231, 1987
105. Masuda M, Komiyama Y, Murakami T, Murata K: Decrease of polymorphonuclear leukocyte membrane fluidity in uremic patients on hemodialysis. Nephron 54:36-41, 1990
106. Jörstad S, Viken KE: Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand 85C:169-177, 1977
107. Jörstad S, Kvemes S: Uraemic toxins of high molecular weight inhibiting human mononuclear phagocytes cultured in vitro. Acta Pathol Microbiol Scand 860:221-226, 1978
108. Jörstad S, Smeby LC, Wideröe TE, Berg KJ: Transport of uremic toxins through conventional hemodialysis membranes. Clin Nephrol 12:168-173, 1979
109. Porter CJ, Burden RP, Morgan AG, el al: Impaired polymorphonuclear neutrophil function in end-stage renal failure and its correction by continuous ambulatory peritoneal dialysis. Nephron 71:133-137, 1995
110. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87:6353-6357, 1990
111. Haag-Weber M, Mai B, Cohen G, Hörl WH: GIP and DIP: A new view of uraemic toxicity. Nephrol Dial Transplant 9:346-347, 1994
112. 2-microglobulinNephrol Dial Transplant 9:382-388, 1994
113. Beimler J, Schaefer RM, Haag-Weber M, Hörl WH: Effect of granulocyte inhibiting proteins from uremic patients on mononuclear cell cytokine production. 1996 (submitted)
114. Haag-Weber M, Mai B, Hörl WH: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 9:1769-1773, 1994
115. Tschesche H, Kopp C, Hörl WH, Hempelmann U: Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 269:30274-30280, 1994
116. Hörl WH, Bläser J, Tschesche H: Role of angiogenin, a degranulation inhibiting protein of polymorphonuclear leukocytes, in renal failure patients, (submitted)
117. Balke N, Holtkamp U, Hörl WH, Tschesche H: Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. FEBS Letters 371:300-302, 1995
118. Volanakis JE, Barnum SR, Giddens M, Galla JH: Renal filtration and catabolism of complement protein. N Engl J Med 312:395-399, 1985
119. Cohen G, Haag-Weber M, Mai B, el al: Effect of immunoglobulin light chains from hemodialysis and CAPD patients on PMNL functions. J Am Soc Nephrol 6:1592-1599, 1995
120. Hannam-Harris AC, Gordon J, Smith JL: Immunoglobulin synthesis by neoplastic B lymphocytes: Free light chain synthesis as a marker of B cell differentiation. J Immunol 125:2177-2181, 1980
121. Peterson PA, Berggard I: Urinary immunoglobulin components in normal, tubular and glomerular proteinuria: Quantities and characteristics of free light chain, IgG, IgA, and Fc-lambda fragment. J Eur Clin Invest 1:255-264, 1971
122. Solling K: Free light chains of immunoglobulins. Scand J Clin Lab Invest 157:1-83, 1981 (Suppl 1)
123. Wakasugi K, Sasaki M, Suzuki M, el al: Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients. Biomater Artif Cells Immobilization Biotechnol 19:97-109, 1991